BACKGROUND: Mutations in parkin and PTEN-induced protein kinase (PINK1) represent the two most common causes of autosomal recessive parkinsonism. The possibility that heterozygous mutations in these genes also predispose to disease or lower the age of disease onset has been suggested, but currently there is insufficient data to verify this hypothesis conclusively. OBJECTIVE: To study the frequency and spectrum of parkin and PINK1 gene mutations and to investigate the role of heterozygous mutations as a risk factor for early-onset Parkinson's disease (PD). METHODS: All exons and exon-intron boundaries of PINK1 and parkin were sequenced in 250 patients with early-onset PD and 276 normal controls. Gene dosage measurements were also performed, using high-density single-nucleotide polymorphism arrays. RESULTS: In total 41 variants were found, of which 8 have not been previously described (parkin: p.A38VfsX6, p.C166Y, p.Q171X, p.D243N, p.M458L; PINK1: p.P52L, p.T420T, p.A427E). 1.60% of patients were homozygous or compound heterozygous for pathogenic mutations. Heterozygosity for pathogenic parkin or PINK1 mutations was over-represented in patients compared with healthy controls (4.00% vs. 1.81%) but the difference was not significant (p = 0.13). The mean age at disease onset was significantly lower in patients with homozygous or compound heterozygous mutations than in patients with heterozygous mutations (mean difference 11 years, 95% CI 1.4 to 20.6, p = 0.03). There was no significant difference in the mean age at disease onset in heterozygous patients compared with patients without a mutation in parkin or PINK1 (mean difference 2 years, 95% CI -3.7 to 7.0, p = 0.54). CONCLUSIONS: Our data support a trend towards a higher frequency of heterozygosity for pathogenic parkin or PINK1 mutations in patients compared with normal controls, but this effect was small and did not reach significance in our cohort of 250 cases and 276 controls.
BACKGROUND: Mutations in parkin and PTEN-induced protein kinase (PINK1) represent the two most common causes of autosomal recessive parkinsonism. The possibility that heterozygous mutations in these genes also predispose to disease or lower the age of disease onset has been suggested, but currently there is insufficient data to verify this hypothesis conclusively. OBJECTIVE: To study the frequency and spectrum of parkin and PINK1 gene mutations and to investigate the role of heterozygous mutations as a risk factor for early-onset Parkinson's disease (PD). METHODS: All exons and exon-intron boundaries of PINK1 and parkin were sequenced in 250 patients with early-onset PD and 276 normal controls. Gene dosage measurements were also performed, using high-density single-nucleotide polymorphism arrays. RESULTS: In total 41 variants were found, of which 8 have not been previously described (parkin: p.A38VfsX6, p.C166Y, p.Q171X, p.D243N, p.M458L; PINK1: p.P52L, p.T420T, p.A427E). 1.60% of patients were homozygous or compound heterozygous for pathogenic mutations. Heterozygosity for pathogenic parkin or PINK1 mutations was over-represented in patients compared with healthy controls (4.00% vs. 1.81%) but the difference was not significant (p = 0.13). The mean age at disease onset was significantly lower in patients with homozygous or compound heterozygous mutations than in patients with heterozygous mutations (mean difference 11 years, 95% CI 1.4 to 20.6, p = 0.03). There was no significant difference in the mean age at disease onset in heterozygous patients compared with patients without a mutation in parkin or PINK1 (mean difference 2 years, 95% CI -3.7 to 7.0, p = 0.54). CONCLUSIONS: Our data support a trend towards a higher frequency of heterozygosity for pathogenic parkin or PINK1 mutations in patients compared with normal controls, but this effect was small and did not reach significance in our cohort of 250 cases and 276 controls.
Authors: Sarah J Lincoln; Demetrius M Maraganore; Timothy G Lesnick; Rebecca Bounds; Mariza de Andrade; James H Bower; John A Hardy; Matthew J Farrer Journal: Mov Disord Date: 2003-11 Impact factor: 10.338
Authors: T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu Journal: Nature Date: 1998-04-09 Impact factor: 49.962
Authors: T Foroud; S K Uniacke; L Liu; N Pankratz; A Rudolph; C Halter; C Shults; K Marder; P M Conneally; W C Nichols Journal: Neurology Date: 2003-03-11 Impact factor: 9.910
Authors: Christine Klein; Ana Djarmati; Katja Hedrich; Nora Schäfer; Cesa Scaglione; Roberta Marchese; Norman Kock; Birgitt Schüle; Anja Hiller; Thora Lohnau; Susen Winkler; Karin Wiegers; Robert Hering; Peter Bauer; Olaf Riess; Giovanni Abbruzzese; Paolo Martinelli; Peter P Pramstaller Journal: Eur J Hum Genet Date: 2005-09 Impact factor: 4.246
Authors: F Binkofski; K Reetz; C Gaser; R Hilker; J Hagenah; K Hedrich; T van Eimeren; A Thiel; C Büchel; P P Pramstaller; H R Siebner; C Klein Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: Christine Klein; Katja Lohmann-Hedrich; Ekaterina Rogaeva; Michael G Schlossmacher; Anthony E Lang Journal: Lancet Neurol Date: 2007-07 Impact factor: 44.182
Authors: Aida M Bertoli-Avella; José L Giroud-Benitez; Ali Akyol; Egberto Barbosa; Onno Schaap; Herma C van der Linde; Emilia Martignoni; Leonardo Lopiano; Paolo Lamberti; Emiliana Fincati; Angelo Antonini; Fabrizio Stocchi; Pasquale Montagna; Ferdinando Squitieri; Paolo Marini; Giovanni Abbruzzese; Giovanni Fabbrini; Roberto Marconi; Alessio Dalla Libera; Giorgio Trianni; Marco Guidi; Antonio De Gaetano; Gustavo Boff Maegawa; Antonino De Leo; Virgilio Gallai; Giulia de Rosa; Nicola Vanacore; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink; Vincenzo Bonifati Journal: Mov Disord Date: 2005-04 Impact factor: 10.338
Authors: V Bonifati; C F Rohé; G J Breedveld; E Fabrizio; M De Mari; C Tassorelli; A Tavella; R Marconi; D J Nicholl; H F Chien; E Fincati; G Abbruzzese; P Marini; A De Gaetano; M W Horstink; J A Maat-Kievit; C Sampaio; A Antonini; F Stocchi; P Montagna; V Toni; M Guidi; A Dalla Libera; M Tinazzi; F De Pandis; G Fabbrini; S Goldwurm; A de Klein; E Barbosa; L Lopiano; E Martignoni; P Lamberti; N Vanacore; G Meco; B A Oostra Journal: Neurology Date: 2005-07-12 Impact factor: 9.910
Authors: Enza Maria Valente; Sergio Salvi; Tamara Ialongo; Roberta Marongiu; Antonio Emanuele Elia; Viviana Caputo; Luigi Romito; Alberto Albanese; Bruno Dallapiccola; Anna Rita Bentivoglio Journal: Ann Neurol Date: 2004-09 Impact factor: 10.422
Authors: Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday Journal: Nat Med Date: 2010-05-23 Impact factor: 53.440
Authors: Kye-Young Kim; Mark V Stevens; M Hasina Akter; Sarah E Rusk; Robert J Huang; Alexandra Cohen; Audrey Noguchi; Danielle Springer; Alexander V Bocharov; Tomas L Eggerman; Der-Fen Suen; Richard J Youle; Marcelo Amar; Alan T Remaley; Michael N Sack Journal: J Clin Invest Date: 2011-08-25 Impact factor: 14.808
Authors: Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan B Bressman; William K Scott; Caroline Tanner; Susan Mickel; Howard Andrews; Cheryl Waters; Stanley Fahn; Lucien Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Karen Marder; Lorraine N Clark Journal: Arch Neurol Date: 2010-09
Authors: Lynne Krohn; Francis P Grenn; Mary B Makarious; Jonggeol Jeffrey Kim; Sara Bandres-Ciga; Dorien A Roosen; Ziv Gan-Or; Mike A Nalls; Andrew B Singleton; Cornelis Blauwendraat Journal: Neurobiol Aging Date: 2020-03-10 Impact factor: 4.673